Archive | Uncategorized RSS feed for this section

Announcing Early Stage “Investor Line-Up” For RESI Europe, Paris On March 23rd

30 Jan

By Claire Jeong, Director of Research, Asia BD, LSN

claireAfter finishing off our most successful RESI to date and recovering from JPM week, we are ramping up our preparations for the upcoming RESI Europe Conference, which will be at the Hyatt Regency Paris Étoile on Monday, March 23rd, 2020. We expanded into Europe for the first time last year, and it is super exciting to be able to go to Paris for our second European conference. We look forward to fostering valuable connections and relationships, as well as working with a lot of new companies and investors/strategic partners based in Europe.

We are anticipating over 200 investors to join us at the event from across the globe. Please take advantage of our Super Early Bird Rate by using our €100 discount code SUPEREBEU on our registration here (expires on Sunday, February 2nd). Hope to see you in Paris!


As of  January 30th, 2020

RESI Europe 2020 Investor Logos 013020

And More…

Sales & Marketing 101: The Skills Entrepreneurs Need To Get Meetings With Investors

30 Jan

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

All global incubators and accelerators will soon be up against an emerging global trend, where there are exponentially more fundable technology assets then investors and channel partners. I have been watching this develop over the 7 years I have been running RESI and in deep dialogue with the global investor market. I truly believe that ONLY the best prepared and packaged companies who are plugged into a global funding network will get the cash and partnerships needed to reach the market.

The LSN message, based on RESI, our dialogue with investors and strategic partners, and our training program, is to get early stage innovators in front of as many potential partners as possible (that are a fit) and that this interaction will create compelling relationships that can lead to capital allocations and licensing deals. LSN training programs are a bit different than then other entrepreneurial programs; essentially, the LSN theme is to take the scientist-entrepreneurs and teach them a small but gigantically important portion of basic sales, marketing and business development 101. We know they will not turn into sales experts, but we can get them some basic sales, marketing, and business development knowledge. Below are some of the main differentiators that LSN offers:

  • How to get a list of partners that are a fit for your stage of development and product set. LSN Investor Platform has 5K global profiles
  • How to define your competitive landscape. LSN Business Development Platform has 55K profiles
  • How to set up a CRM to “manage and curate that list” of potential partners that are a fit and you need to reach as part of an ongoing campaign
  • How to create and execute an email and phone canvassing. Yes, we teach how to write an intro email and how to pick up phone and make a call in our training labs
  • How to do follow up calls, and then teach how to make the 2 to 20 follow up calls that need to be made
  • How to use the RESI partnering system effectively to get as many meetings as possible

I think LSN has a bit of a different view and philosophy. All the branding and messaging LSN teaches is just to get partner meetings. That is it: essentially, how to organize your company’s branding and messaging to get in front of the right players and have that first meeting. I think the still commonly used broader, more sophisticated approach of figuring out the valuation and market size as part of their coaching is not where you want to spend a majority of your time. Predicting future sales and market size when you are preclinical, nascent startup is blindfolded forecasting. Rather, we teach PhDs to concentrate on getting the technology turned into a prototype with compelling proof of concept (data) that can be shown to the market players. Enter LSN, that connects the scientist-entrepreneur to the market player. The market players, if interested, will help determine value as the data and product takes shape and the relationship develops. LSN believes that if the fit is there, both parties will work together to achieve maximum success for the product and the market.

LSN Launches New Health Innovation Event – 4D Meets AI (September 22nd)

30 Jan

By Chris Kennedy, Vice President Strategic Initiatives, 4D Meets AI, LSN

chris headshotLSN is taking a strategic step forward in 2020 and introducing 4D Meets AI, a new one day conference event that will stand beside RESI Boston in September.

Artificial Intelligence (AI) is a transformative force in the healthcare industry. From hospital care to clinical research, drug development and pathology,  AI applications are revolutionizing how the health sector works to reduce spending and improve patient outcomes.

The 4D Meets AI conference is organized around those early stage companies in the Drug, Device, Diagnostic and Digital Health verticals, the “4Ds”, companies that are pursuing the integration of technology, using new tools and applying methodologies that AI brings to this dynamic sector. AI will fundamentally reshape the healthcare landscape as we know it today.

LSN created the 4D Meets AI conference stemming from the success of our long-standing RESI conference series. It will continue doing what LSN does best, connecting early stage companies that develop cutting-edge AI technology in drugs, devices, diagnostics and digital health with the right investors, decision makers and thought leaders in this dynamic developing landscape.

We will launch registration soon, so stay tuned!  4D Meets AI is a unique opportunity to connect with early stage companies and investors in the healthcare AI space; if you are interested in sponsoring the event to boost your visibility, please reach out to me at

graphic 4dai

Hot Investor Mandate: NY Private Investment Firm Invests To Lower The Cost Of Care

30 Jan

A private investment firm based in New York invests in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: London PE Firm Invests In Innovative Medical Services

30 Jan

A private equity firm based in London, UK that focuses exclusively on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is technology and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Asia Family Office-Backed Firm Invests in Life Science Platforms

30 Jan

A biotech early stage investment fund founded in 2016 and headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Transatlantic Venture Firm Invests Opportunistically In Medtech And Digital Health

30 Jan

A transatlantic investment firm based in the Netherlands with an additional operation in Boston, USA, is investing from a fund of over $250 million.  The firm prefers to invest in commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: